A Review on the Update of Combined Hepatocellular Cholangiocarcinoma.


Journal

Seminars in liver disease
ISSN: 1098-8971
Titre abrégé: Semin Liver Dis
Pays: United States
ID NLM: 8110297

Informations de publication

Date de publication:
May 2020
Historique:
pubmed: 31 12 2019
medline: 23 3 2021
entrez: 31 12 2019
Statut: ppublish

Résumé

Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a primary liver tumor with neoplastic components of both hepatocytic and cholangiocytic differentiation. This unique neoplasm is gaining increasing recognition due to the intriguing pathology, tumor biology, and clinical behavior. It also poses challenges in diagnosis, treatment, and research, largely because of its histological and phenotypic diversity that lead to confusion in terminology and classification. There have been efforts attempting to unify the terminology of this neoplasm recently. Advances in investigation in various aspects have also been made. This review aims to update the terminology, classification, and clinical and pathological characteristics of cHCC-CCA.

Identifiants

pubmed: 31887773
doi: 10.1055/s-0039-3402515
doi:

Substances chimiques

Biomarkers, Tumor 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

124-130

Informations de copyright

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Déclaration de conflit d'intérêts

Both authors have no conflicts of interest to declare.

Auteurs

Mina Komuta (M)

Department of Pathology, Cliniques Universitaires Saint-Luc/Université Catholique de Louvain, Brussels, Belgium.

Matthew M Yeh (MM)

Department of Pathology, University of Washington School of Medicine, Seattle.
Department of Medicine, University of Washington School of Medicine, Seattle.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH